|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 46.99 USD | +0.02% |
|
-.--% | - |
| 12-15 | Immunome jumps after promising results for its desmoid tumor treatment |  |
| 12-01 | Tyra Bioscience Appoints Bhavesh Ashar as Chief Operating Officer | MT |
Business description: SpringWorks Therapeutics, Inc.
Number of employees: 368
Sales by Activity: SpringWorks Therapeutics, Inc.
| Fiscal Period: December | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|
Developing and Commercializing Life-Changing Medicines | 35M | - | - | 5.45M | 192M |
Geographical breakdown of sales: SpringWorks Therapeutics, Inc.
| Fiscal Period: December | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|
United States | 35M | - | - | 5.45M | 192M |
Executive Committee: SpringWorks Therapeutics, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Kim Diamond
IRC | Investor Relations Contact | - | 31/07/2018 |
Company details: SpringWorks Therapeutics, Inc.
Biopharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.02% | -.--% | +24.51% | +96.36% | 3.54B | |
| -1.05% | -2.85% | +35.81% | -10.05% | 76.55B | |
| 0.00% | -5.93% | +89.80% | +194.65% | 57.99B | |
| +0.87% | +61.60% | +61.60% | +61.60% | 50.58B | |
| -0.31% | -1.48% | -42.71% | -54.57% | 47.3B | |
| -2.50% | -0.62% | +52.68% | -38.91% | 25.83B | |
| +0.77% | +6.63% | +117.07% | -65.19% | 21.69B | |
| -1.83% | -1.69% | +65.11% | +27.95% | 18.97B | |
| +0.36% | +1.92% | +57.41% | +52.65% | 15.55B | |
| -0.24% | +2.64% | +128.98% | +425.85% | 15.03B | |
| Average | -0.39% | +0.70% | +59.03% | +69.03% | 33.3B | |
| Weighted average by Cap. | -0.40% | -0.55% | +51.34% | +50.22% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Equities
- SWTX Stock
- Company SpringWorks Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition